Morgan Stanley lowered the firm’s price target on Align Technology (ALGN) to $280 from $310 and keeps an Overweight rating on the shares. Shares “may ebb on disappointing volume” and Q4 targets that were below the firm’s and Street’s view amid a continuing sluggish demand backdrop, but expectations were low and the company is stepping up the buyback and pointing to margin improvement in 2025, while “addressing areas under its control,” the analyst tells investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALGN:
- Align Technology price target lowered to $275 from $285 at Stifel
- Align Technology price target lowered to $275 from $285 at Piper Sandler
- Align Technology price target lowered to $276 from $325 at Baird
- Align Technology sees Q4 revenue $995M-$1.015B, consensus $1.01B
- Align Technology introduces Invisalign Smile Architect